
Immunocore
Oxfordshire biotech whose Kimmtrak became the first approved T-cell receptor drug, in 2022.
Last refreshed: 14 November 2026
Can T-cell receptor drugs repeat Kimmtrak's success beyond one tissue type?
Timeline for Immunocore
T-Therapeutics raises $133m in Series B
UK Startups and InnovationBackground
Immunocore, an Oxfordshire biotech, won US approval in January 2022 for Kimmtrak, the first T-cell receptor drug and the first bispecific T-cell engager approved for a solid tumour. It treats uveal melanoma, but only in patients with the HLA-A*02:01 tissue type, about half of those with the disease.
An Oxford spinout, it raised about $320m privately in 2015, then the largest private financing for a European biotech, and listed on Nasdaq in February 2021. Briefings cite it as the precedent for T-Therapeutics and other British companies working on the same class of molecule.
What is Kimmtrak?
When did Immunocore go public?
Which patients can take Kimmtrak?
Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 14 November 2026. Editorial standards.